Stabilization of atherosclerotic plaque during lipid lowering

Current Opinion in Lipidology

Volumn 8, Issue 6, 1997, Pages 348-353

  Müller Wieland, Dirk ^a   Kotzka, Jörg ^a   Krone, Wilhelm ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BINDING PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CORONARY ARTERY OBSTRUCTION; ENDOTHELIUM; GENE CONTROL; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SHORT SURVEY; THROMBOGENESIS;

THROMBUS;

EID: 0030735211     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199712000-00005     Document Type: Short Survey

References (51)

1. Watts GF, Burke V: Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996, 7:341-355
2. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA 1997, 278:313-321.
3. Brown BG, Zhao X-Q, Sacco BE, Albers JJ: Lipid lowering and plaque regression and new insights into prevention of plaque disruption and clinical events in coronary heart disease. Circulation 1993, 87:1781-1791.
4. O'Keefe JH Jr, Conn RD, Lavie CJ Jr, Maeman TM: The new paradigm for coronary artery disease: altering risk factors, atherosclerotic plaques, and clinical prognosis. Mayo Clin Proc 1996, 71:957-965.
5. Kannel WB: Incidence, prevalence, and mortality of coronary artery disease. In Atherosclerosis and Coronary Artery Disease 1st edn. Edited by Fuster V, ROSS R, Topol EJ. Philadelphia: Lippincott-Raven Publishers; 1996, 1:13-24.
6. Davies MJ Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995. Circulation 1996, 94:2013-2020.
7. Mann JM, Davies MJ: Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996, 94:928-931.
8. Libby P: Molecular basis of the acute coronary syndrome. Circulation 1995, 91:2844-2850.
9. Guyton JR, Klemp KF: Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996, 16:4-11.
10. Falke E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995, 92:657-671.
11. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P: Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol 1996, 7:389-397.
12. Brown MS, Goldstein JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89:331-340. This outstanding review provides a brilliant overlook concerning the role of SREBPs in cell biology, metabolism and diseases.
13. Stary HC, Blankenhorn DH, Chandler BA, Glagov S, Insul W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwarz CJ, Wagner WD et al.: A definition of the intima of human arteries and of its atherosclerosis-prone regions. Circulation 1992, 85:391-405.
14. Stary HC, Chandler BA, Glagov S, Guyton JR, Insul W Jr, Rosenfeld ME, Schaffer SA, Schwarz CJ, Wagner WD, Wissler RW: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. Artherioscler Thromb 1994, 14:840-856.
15. Stary HC, Chandler BA, Dinsmure RE, Fuster V, Glagov S, Insul W Jr, Rosenfeld ME, Schwarz CJ, Wagner WD, Wissler RW: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 1995, 92:1355-1374.
16. Okamoto T, Akaike T, Suga M, Tanase S, Horiet H, Miyajima S, Ando M, Ichinose Y, Maeda H: Activation of human matrix metalloproteinase by various bacterial proteinases. J Biol Chem 1997, 272:6059-6066.
17. Sohwartz MS: Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997, 99:2814-2817.
18. Risau W: Mechanisms of angiogenesis. Nature 1997, 386:671-674.
19. Vaughan CJ, Murphy MB, Buckey BM: Statins do more than just lower cholesterol. Lancet 1996, 348:1079-1082. This paper summarizes the current evidence that statins might have direct effects on the vascular wall and blood constituents.
20. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131.
21. Tamai O, Mastsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T: Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997, 95:76-82.
22. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997, 95:324-328.
23. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL: Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997, 29:846-854. For the first time direct evidence is provided that members of SREBPs have differential transcriptional activity.
24. Sakai J, Duncan EA, Rawson RB, Hua X, Brown MS, Goldstein JL: Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 1996, 85:1037-1046. This paper characterizes the cleavage mechanism of SREBPs and might be of general significance for the regulation of transcription factors.
25. Kim JB, Spotts GD, Halvorsen YD, Shih HM, Ellenberger T, Towle HC, Spiegelman BM: Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain. Mol Cell Biol 1995, 15:2582-2588.
26. Magana MM, Osborne IF: Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter. J Biol Chem 1996, 271:32689-32694.
27. Vallet SM, Sanchez HB, Rosenfeld JM, Osborne TF: A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene. J Biol Chem 1996, 271:12247-12253.
28. Yokoyma C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS: SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993, 75:187-197.
29. Spear DH, Ericsson J, Jackson SM, Edwards PA: Identification of a 6-base pair element involved in the sterol-mediated transcriptional regulation of farnesyl diphosphate synthase. J Biol Chem 1994, 269:25212-25218.
30. Jackson SM, Ericsson J, Metherall JE, Edwards PA: Role for sterol regulatory element binding protein in the regulation of farnesyl diphosphate synthase and in the control of cellular levels of cholesterol and triglyceride: evidence from sterol regulation-defective cells. J Lipid Res 1996, 37:1712-1721.
31. Lopez JM, Bennett MK, Sanchez HB, Rosenfeld JM, Osborne TF: Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc Natl Acad Sci USA 1996, 93:1049-1053.
32. Bennett MK, Lopez JM, Sanchez HB, Osborne TF: Sterol regulation of fatty acid synthase promoter. J Biol Chem 1995, 270:25578-25583.
33. Ericsson J, Jackson SM, Kim JB, Spiegelman BM, Edwards PA: Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene. J Biol Chem 1997, 272:7298-7305.
34. Sato R, Inoue J, Kawabe Y, Kodama T, Takano T, Maeda M: Steroldependent transcriptional regulation of sterol regulatory element-binding protein-2. J Biol Chem 1996, 271:26461-26464.
35. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS: Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997, 29:838-845.
36. Sanchez HB, Yieh L, Osborne TF: Cooperation by sterol regulatory element-binding protein and Sp1 in sterol regulation of low density lipoprotein receptor gene. J Biol Chem 1995, 270:1161-1169.
37. Yieh L, Sanchez HB, Osborne TF: Domains of transcription factor Sp1 required for synergistic activation with sterol regulatory element binding protein 1 of low density lipoprotein receptor promoter. Proc Natl Acad Sci USA 1995, 92:6102-6106.
38. Jackson SM, Ericsson J, Osborne TF, Edwards PA: NF-Y has a novel role in sterol-dependent transcription of two cholesterogenic genes. J Biol Chem 1995, 270:21445-21448.
39. Oliner JD, Andresen JM, Hansen SK, Zhou S, Tjian R: SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein. Genes Dev 1996, 10:2903-2911
40. Basheeruddin K, Xiaoli L, Rechtoris C, Mazzone T: Platelet-derived growth factor enhances Sp1 binding to the LDL receptor gene. Arterioscler Thromb Vasc Biol 1995, 15:1248-1254.
41. Kim JB, Spiegelman M: ADD1/SREBP1 promotes adipocyte diflerentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996, 10:1096-1107. This paper provides direct evidence that a cholesterol regulated transcription factor can determine adipocyte differentiation. This might have clinical implications for the development of obesity.
42. Streicher R, Kotzka J, Müller-Wieland D, Siemeister G, Munck M, Avci H, Krone W: SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-1. J Biol Chem 1996, 271:7128-7133. This paper shows for the first time that SREBPs are direct mediators of the effects of insulin and growth factors on the LDL receptor promotor and modulate the action of cholesterol synthesis inhibitors.
43. Lloyd DB, Thompson JF: Transcriptional modulators affect in vivo protein binding to the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase promoters. J Biol Chem 1995, 270:25812-25818.
44. Sheng Z, Otani H, Brown MS, Goldstein JL: Independent regulation of sterol regulatory element-binding proteins 2 and 1 in hamster liver. Proc Natl Acad Sci USA 1995, 92:935-938.
45. Tontonoz P, Kim JB, Graves RA, Spiegelman BM: ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol 1993, 13:4753-4759.
46. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
47. Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture. Cell 1996, 5:377-389. This excellent review gives an overview concerning the principal concepts and significance of transcription factors in adipocyte differentiation and the development of obesity, including perspectives for new drug targets.
48. Brun RP, Kim JB, Hu E, Spiegelman BM: Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Curr Opin Lipidol 1997, 8:212-218.
49. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear receptor PPARγ. J Biol Chem 1995, 270:12953-12956
50. Mukherjee R, Davies PJA, Cromble DL, Bischoff ED, Cesarlo RM, Jow L, Hamanns LG, Boehm MF, Mondon CE, Nadzan AM et al.: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997, 386:407-410.
51. Zechner R: The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. Curr Opin Lipidol 1997, 8:77-88.